



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

MAR 20 1992

#33

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fisher's Lane, Room 11-44
Rockville, MD 20857

Dear Mr. Wilson:

The enclosed application for extension of the patent term of U.S. Patent No. 4,761,418 issued on August 2, 1988, was filed on March 16, 1992, under 35 USC § 156. A Supplemental Declaration (enclosed) was filed on March 20, 1992.

Your assistance is requested in confirming that the product identified in the application has been subject to a regulatory review period within the meaning of 35 USC § 156 (g) before its commercial marketing or use. Since a determination has not been made whether the patent in question claims a product which is subject to the Federal Food, Drug and Cosmetic Act, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 USC § 156 (d) (2) (A).

Our review of the application to date indicates that the subject matter would be eligible for extension of the patent term under 35 USC § 156.

C. E. Van Horn

Charles E. Van Horn
Patent Policy & Programs Administrator
Office of the Assistant Commissioner for Patents

cc: Dr. L.A. Nielsen
Burroughs Wellcome Co.
3030 Cornwallis Road
Research Triangle Park, NC 27709
Celebrating 200 Years of Promoting Creativity 1790-1990